A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

Recruiting

Phase 2

Zanidatamab & ChemotherapyA Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

Sponsor:

Jazz Pharmaceuticals

Code:

NCT07102381

Conditions

HER2-positive Breast Cancer

Breast Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Zanidatamab

Paclitaxel

Docetaxel

Carboplatin

Trastuzumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-10-10. This information was provided to ClinicalTrials.gov by Jazz Pharmaceuticals on 2025-10-07.